Crosstalk Between Platelets and Brain Tumor Initiating Cells in Glioblastoma
胶质母细胞瘤中血小板与脑肿瘤起始细胞之间的串扰
基本信息
- 批准号:8907582
- 负责人:
- 金额:$ 4.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2018-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAntibodiesAreaAutomobile DrivingBiologicalBiological AssayBlood CirculationBlood PlateletsBlood VesselsBrainBrain NeoplasmsCell CommunicationCellsCellular biologyClinicalClinical ResearchDataDevelopmentDiseaseEnvironmentEpidermal Growth Factor ReceptorEventExhibitsGeneticGlioblastomaGrowthGrowth Factor ReceptorsHeterogeneityHistologicHumanHypoxiaIn VitroInvadedLaboratoriesLesionLocationMediatingMolecularMusNecrosisNeoplasm Circulating CellsNeoplasm MetastasisNeuraxisNon-MalignantOutcomePatientsPhenotypePhosphorylationPlatelet Count measurementPrognostic MarkerRNARNA InterferenceRecurrenceResistanceRoleSignal TransductionSpecimenStem cellsTestingTherapeuticTumor Burdenbasecancer therapycell growthcell motilitydensitydesigndriving forceimprovedin vivoinhibitor/antagonistneoplastic cellnerve stem cellnoveloutcome forecastpalliativepublic health relevanceregenerativeresponseself-renewalstemnesstraittumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Glioblastomas (GBM) exhibit a remarkable tumor cell heterogeneity, which contributes to the overall regenerative and aggressive disease traits. Recent studies in our laboratory's and others' strongly support the existence of a cellular hierarchy within GBM in which brain tumor initiating cells (BTICs) at the apex are the driving force of disease recurrence and resistance to current therapies. It is imperative to consider the intimate and dynamic interactions between BTICs and their immediate environments in perivascular, hypoxic, and necrotic regions within the tumor. These locations serve as functional niches for BTICs and facilitate access to various factors and interacting partners that promote their growth- and ultimately of the overall tumor. While clinical studies have uncovered high platelet counts as a negative prognostic marker for survival outcomes in GBM patients, there is no study to functionally elucidate a role for platelets in this highly aggressive disease. The proposed studies aim to uncover a biological role for platelets in driving the growth and stemness qualities specifically of BTICs, which have been histologically detected in BTIC-related niches in primary clinical specimens. As location serves a strong purpose within the context of BTICs, successful characterization of potential crosstalk between platelets and BTICs will offer a new clinical perspective into GBM and inform of a novel treatment paradigm to target these specific cell-to-cell interactions. The development of effective therapeutics to disrupt platelets-BTIC interactions may improve the long-term clinical outcomes of GBM patients undergoing current standard therapies.
描述(由申请人提供):胶质母细胞瘤(GBM)表现出显著的肿瘤细胞异质性,这有助于整体再生和侵袭性疾病特征。我们实验室和其他实验室的最新研究强烈支持GBM内存在细胞层次结构,其中位于顶点的脑肿瘤起始细胞(BTIC)是疾病复发和对当前治疗耐药的驱动力。必须考虑BTIC与其在肿瘤内血管周围、缺氧和坏死区域中的直接环境之间的密切和动态相互作用。这些位置作为BTIC的功能小生境,并促进获得各种因子和相互作用的伙伴,促进其生长-并最终促进整个肿瘤的生长。虽然临床研究已经发现高血小板计数是GBM患者生存结局的阴性预后标志物,但没有研究从功能上阐明血小板在这种高度侵袭性疾病中的作用。拟议的研究旨在揭示血小板在驱动BTIC特别是BTIC的生长和干性质量方面的生物学作用,BTIC已在主要临床标本中的BTIC相关小生境中进行了组织学检测。由于定位在BTIC的背景下起着重要作用,因此血小板和BTIC之间潜在串扰的成功表征将为GBM提供新的临床视角,并为靶向这些特定细胞间相互作用的新治疗范式提供信息。开发破坏血小板-BTIC相互作用的有效治疗方法可能会改善接受当前标准治疗的GBM患者的长期临床结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTINE H LEE其他文献
CHRISTINE H LEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTINE H LEE', 18)}}的其他基金
Crosstalk Between Platelets and Brain Tumor Initiating Cells in Glioblastoma
胶质母细胞瘤中血小板与脑肿瘤起始细胞之间的串扰
- 批准号:
9604457 - 财政年份:2017
- 资助金额:
$ 4.31万 - 项目类别:
Crosstalk Between Platelets and Brain Tumor Initiating Cells in Glioblastoma
胶质母细胞瘤中血小板与脑肿瘤起始细胞之间的串扰
- 批准号:
9035145 - 财政年份:2015
- 资助金额:
$ 4.31万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 4.31万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 4.31万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 4.31万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 4.31万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 4.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 4.31万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 4.31万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 4.31万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 4.31万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 4.31万 - 项目类别:














{{item.name}}会员




